



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## GSK620

Item No. 36139

**CAS Registry No.:** 2088410-46-0  
**Formal Name:** N<sup>5</sup>-cyclopropyl-1,2-dihydro-N<sup>3</sup>-methyl-2-oxo-1-(phenylmethyl)-3,5-pyridinedicarboxamide  
**MF:** C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>  
**FW:** 325.4  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

GSK620 is supplied as a solid. A stock solution may be made by dissolving the GSK620 in the solvent of choice, which should be purged with an inert gas. GSK620 is sparingly soluble (1-10 mg/ml) in DMSO.

### Description

GSK620 is a bromodomain and extra terminal domain family of proteins (BET) bromodomain 2 (BD2) inhibitor (IC<sub>50</sub>s = 316.2, 79.4, 79.4, and 199.5 nM for BRD2, BRD3, BRD4, and BRDT BD2, respectively).<sup>1</sup> It is selective for BD2 in bromodomain-containing protein 2 (BRD2), BRD3, BRD4, and BRDT over BD1 in the same BRDs (IC<sub>50</sub>s = >15,000 nM for all). GSK620 inhibits LPS-induced chemokine (C-C motif) ligand 1 (CCL1) production in isolated human whole blood (IC<sub>50</sub> = 794.3 nM).

### Reference

1. Seal, J.T., Atkinson, S.J., Aylott, H., *et al.* The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) inhibitor. *J. Med. Chem.* **63**(17), 9093-9126 (2020).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/26/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM